AVCT
American Virtual Cloud Technologies Inc
-16.99%
$1.13 - $0.94
Nov 3rd 2022 - Dec 15th 2022
Nov, 22, 2022
The management is top shelf and, if there was not ... See more
Nov, 10, 2022
$AVCT L2 is bull—-shit NDA I MEAN NFA 🥱💨💨💨
NOVN
Novan Inc
-30.70%
$1.71 - $1.19
Feb 7th 2023 - Mar 21st 2023
Mar, 6, 2023
Bullish nda.
Jan, 23, 2023
$NOVN Let’s look at this : NDA filed, Creative fac... See more
HOTH
Hoth Therapeutics Inc
-41.67%
$3.48 - $2.03
Feb 8th 2023 - Mar 22nd 2023
Jan, 3, 2023
$HOTH This is massive opportunity now with FDA N... See more
Jan, 3, 2023
$HOTH cancer FDA NDA approved now so $35-45 is fai... See more
Nov, 22, 2022
The management is top shelf and, if there was not an NDA in place, would have had some sort of bs press release or announcement.
Nov, 10, 2022
$AVCT L2 is bull—-shit NDA I MEAN NFA 🥱💨💨💨
Nov, 4, 2022
$AVCT NDA period 🤐
Mar, 6, 2023
Bullish nda.
Jan, 23, 2023
$NOVN Let’s look at this : NDA filed, Creative factoring financing, marketing partnerships established, Very promising product pipeline… Personally, looks better than it had in a long time.
Jan, 6, 2023
$NOVN NDA was submitted which is great
Jan, 6, 2023
➡️ The NDA was submitted, on time.
Jan, 5, 2023
- Once the NDA for SB206 is submitted this week, price should have no problem breaking $2.25 resistence. .
Dec, 23, 2022
NDA coming soon🚀
Nov, 14, 2022
NDA submission should give us a bump and keep us above as well.
Nov, 14, 2022
$NOVN still on track to submit NDA by year end, which is great because the way this stock has sank it could have been bad if they delayed.
Oct, 31, 2022
$NOVN NDA news pump will be glorious
Jan, 3, 2023
$HOTH This is massive opportunity now with FDA NDA approval for cancer and pending BIOLEXA approval, as well as HOTH now fully funded until 2024.
Jan, 3, 2023
$HOTH cancer FDA NDA approved now so $35-45 is fair value given the market rates Low float and low mkt cap Fully funded into 2024 is huge bonus here Good to be buying below $15 for now
Jan, 3, 2023
$HOTH This is massive opportunity now with FDA NDA approval for cancer and pending BIOLEXA approval, as well as HOTH now fully funded until 2024.